Metabolic Dysfunction-Associated Steatotic Liver Disease and its association with prediabetes in adolescents with obesity
Main Article Content
Keywords
Fatty Liver, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Adolescent , Pediatric Obesity, Ultrasonography
Abstract
Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a complication of obesity and insulin resistance that can lead to serious health implications. The fatty liver index (FLI) and ultrasound have gained relevance for their ability to predict MASLD.
Objective: To analyze the association between MASLD using FLI and ultrasound with the presence of prediabetes in adolescents with obesity.
Methods: Cross-sectional study. Pediatric patients of both sexes, aged 10 to 16 years, with obesity were included. Clinical data and anthropometric measurements were recorded, biochemical variables and FLI were determined, and liver ultrasound was performed using geographic mapping.
Results: A total of 89 patients were analyzed, 46 (51.69%) were male; of the total, 27 (30.3 %) had prediabetes: 56 (62.9 %) had MASLD by FLI, and 62 (69.6 %) had MASLD by ultrasound. The FLI was 67.1 ± 20.3 and was positive in 74 % of adolescents with obesity and prediabetes. MASLD determined by ultrasound was associated with the presence of prediabetes, OR 3.39 (95%CI 1.04 - 11.04), p = 0.04.
Conclusions: MASLD determined by ultrasound, was associated with the presence of prediabetes in adolescents with obesity. In pediatric patients, FLI requires further research to demonstrate its usefulness as a noninvasive complementary marker for the early identification of metabolic liver disorders in patients who also have prediabetes.
References
1. Brecelj J, Orel R. Non-Alcoholic Fatty Liver Disease in Children. Medicina (Kaunas). 2021;57(7):719. doi: 10.3390/medicina57070719.
2. Bernal-Reyes R, Icaza-Chávez ME, Chi-Cervera LA, et al. Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic (dysfunction) associated fatty liver disease: An open population study. Rev Gastroenterol Mex (Engl Ed). 2023;88(3):199-207. doi: 10.1016/j.rgmxen.2022.04.001.
3. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77:1335–47. https://doi.org/10.1097/HEP.0000000000000004
4. Shi GX, Qian YS, Jiang CM, et al. Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents: Authors' name. Sci Rep. 2024;14(1):25724. doi: 10.1038/s41598-024-76922-9.
5. Zhang X, Liu J, Ni Y, et al. Global Prevalence of Overweight and Obesity in Children and Adolescents: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2024;178(8):800-813. doi: 10.1001/jamapediatrics.2024.1576.
6. Shamah-Levy T, Gaona-Pineda EB, Cuevas-Nasu L, et al. Overweight and obesity in Mexican school-aged children and adolescents. Salud Publica Mex. 2024; 66:404-413.https://doi.org/10.21149/15842
7. González-Cortés CA, Cossío-Torres PE, Vargas-Morales JM, et al. Prevalencia de la prediabetes y sus comorbilidades en la población pediátrica mexicana. Nutr Hosp. 2021;38(4):722-728. Spanish. doi: 10.20960/nh.03567.
8. Pedicelli S, Fintini D, Ravà L, et al. Prevalence of prediabetes in children and adolescents by class of obesity. Pediatr Obes. 2022;17(7):e12900. doi: 10.1111/ijpo.12900.
9. Putri RR, Casswall T, Danielsson P, et al. Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes. Diabetes Care. 2024;47(12):2196-2204. doi: 10.2337/dc24-1236.
10. Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol. 2023;78(5):1048-1062. doi: 10.1016/j.jhep.2023.01.024.
11. Arroyave-Ospina JC, Wu Z, Geng Y, et al. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel). 2021;10(2):174. doi: 10.3390/antiox10020174.
12. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19-S40. doi:10.2337/dc23-S002
13.- Dundar C, Terzi O, Arslan HN. Comparison of the ability of HOMA-IR, VAI, and TyG indexes to predict metabolic syndrome in children with obesity: a cross-sectional study. BMC Pediatr. 2023;23(1):74. doi:10.1186/s12887-023-03892-8
14. Ehsan NA, Elsabaawy MM, Sweed DM, et al. Role of liver biopsy in management of liver diseases without hepatic nodules following end of the interferon era: experience of a tertiary referral center. Clin Exp Med. 2023;23(1):97-105. doi: 10.1007/s10238-022-00797-1.
15. Hwang SM, Cho KY. Noninvasive assessment of paediatric hepatic steatosis by using attenuation imaging. Eur Radiol. 2023;33(11):8353-8365. doi: 10.1007/s00330-023-09731-9.
16. Bockarie AS, Nartey YA, Nsiah P, et al. Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients. Endocrinol Diabetes Metab. 2023;6(6):e456. doi: 10.1002/edm2.456.
17. de Silva MHAD, Hewawasam RP, Kulatunge CR, et al. The accuracy of fatty liver index for the screening of overweight and obese children for non-alcoholic fatty liver disease in resource limited settings. BMC Pediatr. 2022;22(1):511. doi:10.1186/s12887-022-03575-w
18. Romero Velarde E, Vásquez Garibay EM, Álvarez Román YA, et al. Circunferencia de cintura y su asociación con factores de riesgo cardiovascular en niños y adolescentes con obesidad. Bol Med Hosp Infant Mex. 2013;70(5):358-363.
19. Centers for Disease Control and Prevention [Internet]. Child and Teen BMI Categories. [Actualizado 28 Jun 2024; citado 13 Oct 2025]. Disponible en: https://www.cdc.gov/bmi/child-teen-calculator/bmi-categories.html
20. Sánchez Escudero V, García Lacalle C, González Vergaz A, et al. El índice triglicéridos-glucosa como marcador de insulinorresistencia en población pediátrica y su relación con hábitos de alimentación y actividad física. Endocrinol Diabetes Nutr. 2021;68:296---303.
21. Carli F, Sabatini S, Gaggini M, et al. Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk. International Journal of Molecular Sciences. 2023; 24(19):14651. https://doi.org/10.3390/ijms241914651
22. Franch-Nadal J, Caballeria L, Mata-Cases M, et al. Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. PLoS One. 2018;13(6):e0198327. doi: 10.1371/journal.pone.0198327.
23. Busquets-Cortés C, Bennasar-Veny M, López-González ÁA, et al. Utility of Fatty Liver Index to predict reversion to normoglycemia in people with prediabetes. PLoS One. 2021;16(4):e0249221. doi:10.1371/journal.pone.0249221.
24. Cuthbertson DJ, Koskinen J, Brown E, et al. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Ann Med. 2021;53(1):1256-1264. doi: 10.1080/07853890.2021.1956685.
25. García-López NA, Jiménez-Álvarez A, Murillo-Zamora E. Detección de hígado graso no alcohólico en niños con sobrepeso y obesidad [Detecting non-alcoholic fatty liver in children with owerweight and obesity.]. Rev Med Inst Mex Seguro Soc. 2021;59(6):465-472. Spanish.
26. Ha Y, Chon YE, Kim MN, et al. Gamma-glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2022;37(8):1624-1632. doi: 10.1111/jgh.15871.
27. Xie J, Pei X, Zhu S, et al. Association of triglyceride-glucose-related indices with adverse clinical outcomes in individuals with normal body mass index. Front Cardiovasc Med. 2025;12:1570239. doi: 10.3389/fcvm.2025.1570239.
28. Trochimczyk K, Flisiak-Jackiewicz M, Bobrus-Chociej A, et al. Biochemical and Anthropometric Indices of Insulin Resistance in Obese and Overweight Children with Metabolic Dysfunction-Associated Fatty Liver Disease. Med Sci Monit. 2024;30:e943375. doi: 10.12659/MSM.943375.
29. H Wacher N, Gómez-Díaz RA, Valdez-González AL, et al. Factores predictivos de MASLD en diabetes tipo 2: estudio de seguimiento de un año [Predictive factors for MASLD in type 2 diabetes: 1 year follow-up study]. Rev Med Inst Mex Seguro Soc. 2024;62(suppl 2):1-12. Spanish. doi: 10.5281/zenodo.10814344.
30. Simental-Mendía LE, Gamboa-Gómez CI, Aradillas-García C, et al. The triglyceride and glucose index is a useful biomarker to recognize glucose disorders in apparently healthy children and adolescents. Eur J Pediatr. 2020;179(6):953-958. doi: 10.1007/s00431-020-03570-2.
31. Pekkarinen L, Kantonen T, Rebelos E, et al. Obesity risk is associated with brain glucose uptake and insulin resistance. Eur J Endocrinol. 2022;187(6):917-928. doi: 10.1530/EJE-22-0509.
32. Hegarty R, Kyrana E, Fitzpatrick E, et al. Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. Ther Adv Endocrinol Metab. 2023;14:20420188231160388.
33. Song K, Kim HS, Chae HW. Nonalcoholic fatty liver disease and insulin resistance in children. Clin Exp Pediatr. 2023;66(12):512-519.
34. Faienza MF, Farella I, Khalil M, et al. Converging Pathways between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Diabetes in Children. International Journal of Molecular Sciences. 2024; 25(18):9924.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.